UPM signs contract to manufacture generic commercial products for Amerigen

Published: 3-Apr-2014
Manufacturing

Eventually all of these products will be manufactured at former Pfizer plant in Bristol, Tennessee


UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings based in Baltimore, MD, US, has agreed to manufacture two ANDA products over a 10-year supply term for Amerigen Pharmaceuticals.

UPM will also develop and potentially commercially supply several additional ANDA products for Amerigen over the next few years.

UPM acquired a 475,000ft2 manufacturing facility in Bristol, Tennessee, US from Pfizer in July 2013 and eventually all of these products will be produced there.

John Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, said: 'UPM has been working with Amerigen for the past three years providing development services for their significant pipeline of ANDA products. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM's transition from a company that formerly focused on only early stage development, but now provides a full range of solid dose commercial services for our clients.'

  • Companies:
  • UPM Pharmaceuticals
  • Amerigen Pharmaceuticals
See more

You may also like

Manufacturing

UPM Pharmaceuticals buys Pfizer plant in Tennessee

Read more
Provides large-scale manufacturing and packaging of tablets and capsules

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Effective ways to optimise heat exchangers Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
  3. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. Ardena's nanomedicines facility marks expansion with first GMP approval The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

UPM Pharmaceuticals buys Pfizer plant in Tennessee

Provides large-scale manufacturing and packaging of tablets and capsules
Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Manufacturing

Degassers for fluidic applications

The range employs a constant vacuum degassing system and can deal with a wide range of flow rates
Manufacturing

Automate LC purification & high-purity compound recovery with UFPLC

The purification instrument allows manufacturers to extract high-purity compounds in a shorter timeframe
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Subscribe now